恒瑞医药：HRS-6257片获批开展用于术后镇痛的临床试验

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs currently approved in the domestic market [1] Group 1 - The subsidiary Shanghai Hengrui Medicine Co., Ltd. has been authorized to conduct clinical trials for HRS-6257 tablets [1] - HRS-6257 is intended for the treatment of acute and chronic pain [1] - There are currently no approved drugs targeting the same mechanism in the domestic market [1]